Shi Rong-Jia, Fan Hua-Yang, Yu Xiang-Hua, Tang Ya-Ling, Jiang Jian, Liang Xin-Hua
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology (Sichuan University), No.14, Sec. 3, Renminnan Road, Chengdu 610041, Sichuan, China.
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Oral Pathology, West China Hospital of Stomatology (Sichuan University), No.14, Sec. 3, Renminnan Road, Chengdu 610041, Sichuan, China.
Biochem Pharmacol. 2022 Jun;200:115039. doi: 10.1016/j.bcp.2022.115039. Epub 2022 Apr 15.
Podophyllotoxin (PPT) has attracted researchers' attention because of its ability to treat various ailments. A series of podophyllotoxin derivatives (PPTs) have been synthesized as candidate drugs to improve the pharmacological characteristics of PPT. Nowadays, an increasing number of reviews have summarized structure-optimization, anticancer application, and single nano delivery of PPT and PPTs. In this review, we focus on the multidirectional pharmacological properties of PPT and PPTs, with an emphasis on the crosstalk with anticancer, anti-inflammatory, immunosuppression, and antivirals. Besides, the newly uncovered mechanisms governing PPT and PPTs in anticancer property including non-apoptotic regulated cell death are discussed. Moreover, their co-delivery nanocarriers with other antitumor drugs or biological agents that have the potential to achieve increased targeting efficacy are included. We hope that a better comprehension of this subject will help to provide a reference for improving the druggability and expanding the clinical application of podophyllotoxin and its derivatives.
鬼臼毒素(PPT)因其治疗多种疾病的能力而引起了研究人员的关注。一系列鬼臼毒素衍生物(PPTs)已被合成作为候选药物,以改善PPT的药理特性。如今,越来越多的综述总结了PPT和PPTs的结构优化、抗癌应用以及单一纳米递送。在本综述中,我们关注PPT和PPTs的多向药理特性,重点是与抗癌、抗炎、免疫抑制和抗病毒作用的相互作用。此外,还讨论了新发现的PPT和PPTs在抗癌特性方面的机制,包括非凋亡调节性细胞死亡。此外,还包括它们与其他具有提高靶向疗效潜力的抗肿瘤药物或生物制剂的共递送纳米载体。我们希望对这一主题有更好的理解将有助于为提高鬼臼毒素及其衍生物的成药性和扩大其临床应用提供参考。